What does BridgeBio Oncology Therapeutics, Inc. do?
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule…
What is BridgeBio Oncology Therapeutics, Inc.'s P/E and P/B ratio?
BridgeBio Oncology Therapeutics, Inc. has a P/E ratio of -40.7 and a P/B ratio of 0.71.
What is BridgeBio Oncology Therapeutics, Inc.'s debt-to-equity ratio?
BridgeBio Oncology Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does BridgeBio Oncology Therapeutics, Inc. owe compared with what it owns?
BridgeBio Oncology Therapeutics, Inc. owes $0.14 for every $1 it owns (balance sheet Jun 2026), which is low.
What is BridgeBio Oncology Therapeutics, Inc.'s Positivity rank?
BridgeBio Oncology Therapeutics, Inc. is ranked #797 of 6,774 companies globally and #133 of 4,000 in United States on PositoAI, with a Positivity Score of 23,725.
Does BridgeBio Oncology Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for BridgeBio Oncology Therapeutics, Inc..
Where can I read the latest news about BridgeBio Oncology Therapeutics, Inc.?
Recent headlines about BridgeBio Oncology Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does BridgeBio Oncology Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of BridgeBio Oncology Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.